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Cell has celebrated the powers of reductionist molecular biology and its major successes for four
decades. Those who have participated in cancer research during this period have witnessed wild
fluctuations from times where endless inexplicable phenomenology reigned supreme to periods
of reductionist triumphalism and, in recent years, to a move back to confronting the endless
complexity of this disease.In the mid-1970s, when Cell published its
first edition, the mechanisms by which
cancer started and spread were a
total mystery. Half a century of cancer
research had generated an enormous
body of observations about the behavior
of the disease, but there were essentially
no insights into how the disease begins
and progresses to its life-threatening
conclusions.
As a result, the field of cancer research
was held in ill-disguised contempt by the
growing crowd of molecular biologists,
geneticists, and biochemists. Even the
cancer researchers had become rather
disillusioned with the vast body of essen-
tially incoherent phenomena that consti-
tuted ‘‘cancer research’’: as one particu-
larly jaundiced cancer researcher told
me at the time ‘‘one should never, ever
confuse cancer research with science!’’
The birth of Cell reflected the growing
confidence that molecular biology would
be able to answer questions that previ-
ously appeared intractable. Despite the
low opinion some had of cancer research,
we molecular biologists imagined that
somehow we would ride in—knights on
white horses—and save the day. We
were, after all, reductionists, who would
parse cancer cells down to their smallest
molecular details and develop useful, uni-
versally applicable lessons about the
mechanisms of cancer development. We
would somehow develop logical order
out of the phenomenological chaos that
the traditional cancer researchers hadbeen accumulating for more than half a
century.
Arrogance like this is never appreci-
ated, and so we tried to keep it under
wraps. We were aware of the sensitivities
of the ruling barons of cancer research
and tried to be nonconfrontational. We
couched our work in molecular biological
terms that were unthreatening for those
who had toiled for generations without
making much headway into the simple
questions of what cancer was and how it
began. We knew, all along, that simple
answers to complex questions would be
greeted with mixed feelings by the large
community of more traditional cancer re-
searchers. After all, if we succeeded, we
might put many of them out of business.
I suppose our self-confidence was
necessary to make our way through
the endless complexity represented by
neoplastic disease: We needed to ignore
the objections that the old-line cancer
researchers repeatedly tossed into our
path; they said that cancer was really
much too complicated to be understood
through simple molecular mechanisms.
Indeed, they portrayed our reductionism
as simplistic if not simple-minded.
At the same time, we were kept honest
by occasional attacks from the left, from
the serious geneticists who were, at the
time, laying the foundation stones of
modern molecular genetics. How could
we pretend, they asked, to be doing
serious, rigorous science if we worked
with genetically ill-defined mammalianCell 15and avian cells? In their minds, only
E. coli, yeast, and Drosophila genetics
held the promise of yielding solid, irrefut-
able conclusions. This sniping from all
sides cemented in my mind the reality
that no matter what one does in life, it is
guaranteed to be wrong in someone’s
eyes.
The molecular cancer story really
began early in the decade—1971 to be
precise—when an enormous pot of
money suddenly became available for
cancer research. President Nixon’s War
on Cancer, as it came to be called, was
fueled by the conviction that cancer was
ultimately a disease of infectious tumor
viruses. By then, it was clear that a diverse
array of viruses carrying DNA or RNA
genomes were able to infect normal
cells and transform them into tumor
cells. Because these transformations
happened in cell cultures, this suggested
that the process of converting a normal
cell into a tumor cell was not confined to
living tissues. One could actually observe
it happening in the Petri dish!
Much of the enthusiasm for launching
the War on Cancer came from the inde-
pendent discoveries by Howard Temin
and David Baltimore that viruses known
to be capable of infecting animals and
triggering tumor formation carried the
reverse transcriptase enzyme (Temin
and Mizutani, 1970; Baltimore, 1970). In
ways that are difficult to reconstruct
now, some portrayed the enzyme as the
key to understanding human cancer. The7, March 27, 2014 ª2014 Elsevier Inc. 267
argument was that relatively simple
assays for this enzyme in human tumor
samples would reveal the elusive retrovi-
ruses that were the underlying causes of
human cancer. It seemed that an under-
standing of the disease of cancer was
finally ripe for the picking.
It’s hard to know now whether the
scientific proponents of the War on
Cancer (officially the National Cancer Act
of 1971) really believed this notion, or
only used it to persuade politicians that
this enzyme provided the critical key to a
definitive understanding of this disease.
For whatever reason, the War was gener-
ously funded by the U.S. government, and
a mad scramble ensued to find reverse
transcriptase and thus the otherwise-
elusive retroviruses lurking in human
tumor samples.
Those working on DNA tumor viruses,
such as polyoma, SV40, adenovirus, and
herpesviruses, jumped on the band
wagon, since the war cry had expanded:
like RNA tumor viruses, viruses with DNA
genomes also played a role in triggering
neoplastic disease. In retrospect, few
seemed deterred by the well-established
observation that most types of human
cancer did not represent communicable
diseases.
By the mid-1970s, with rare exception,
tumor virologists had come up empty-
handed in their search for human retrovi-
ruses. There was some muted grumbling
about overenthusiasm if not outright
deception on the part of those who had
inveigled the US Congress to launch the
War on Cancer in the first place.
The work went on nevertheless,
because of a simple inescapable fact:
the ability of invading viruses to transform
an infected cell dictated that relatively
small viral genomes carrying small
numbers of transforming genes could
drive an infected cell into the neoplastic
growth state. Stated differently, it
appeared that small numbers of viral
genes could somehow overrule the vastly
larger genomes of cells, forcing the
latter into a neoplastic state. This, on its
own, represented a truly revolutionary
concept!
Still, the notion that cancer was a dis-
ease of identifiable genes was little
more than an attractive speculation. The
Varmus-Bishop discovery of the src
proto-oncogene in 1975–1976 changed268 Cell 157, March 27, 2014 ª2014 Elsevierthat (Stehelin et al., 1976). Their work
showed that normal cells carried a gene
that, in principal, could be kidnapped
and corrupted by a marauding retrovirus
and could thereafter drive cancer forma-
tion. This represented yet another enor-
mous leap forward, because it connected
reductionist molecular biology with cell
transformation. Still, its relevance to
human cancer was hardly obvious, since
retroviruses like Rous sarcoma virus
(RSV), in which the src oncogene was
discovered, were impossible to find in
human cancers.
Looking back, it’s clear that the
scramble to find human retroviruses
represented the major irony of the War
on Cancer: it had been launched for the
wrong reason, since cancer-causing
human retroviruses were never found
(with the exception of rare leukemias in
the Caribbean and southern Japan). In
the decades that followed the beginning
of The War, we were able to justify this
wrong-headedness because this War
yielded, in ways that no one could antici-
pate, two enormous benefits.
By the end of the 1970s, the retrovirolo-
gists, stimulated by the Varmus-Bishop
work, began to uncover a growing reper-
toire of proto-oncogenes residing in the
vertebrate genome; these genes would
soon provide a critical entre´e into the
mysteries of human cancer formation
(Bishop, 1983). Moreover, soon after
AIDS was first described in 1981, its etio-
logic agent—HIV—was uncovered with
astonishing rapidity, a direct legacy of
the retrovirology that had been developed
under the aegis of the War on Cancer
during the previous decade (Barre´-
Sinoussi et al., 1983; Gallo et al., 1983).
In my own case, I was energized by the
1973 report of Bruce Ames (Ames et al.,
1973; McCann et al., 1975a, 1975b) and
follow-up studies showing that the carci-
nogenic potency of a chemical species
correlated directly with its mutagenic
activity. This observation represented a
compelling demonstration that cancer
cells were, as some had speculated, actu-
ally mutants, and that the mutant genes
carried by these cells drove malignant
cell proliferation. (Only later was it clear
that, Ames’ work notwithstanding, most
human carcinogens are actually notmuta-
genic, but fortunately I and others were
not derailed by discrepant facts.)Inc.That was the world into which I and
other molecular biologists confidently
strode 40 years ago. Very soon, it
appeared we might be right: the birth of
a malignant cell and its subsequent
spread might indeed be the result of a
few molecular events. Later on, things
got more complicated again. Perhaps
my colleagues and I would never have
begun this work had we known how
complicated things would turn out to be.
Starting in 1973, some in my group
had adapted the then-recently invented
Graham-van der Eb calcium phosphate
transfection technique (used to introduce
genes into mammalian cells; Graham
and van der Eb, 1973) in order to study
retrovirus replication. Indeed, as they
found, transfection of viral DNA—the
product of recent reverse transcription
by infecting retroviruses—could yield
infectious virus particles that were indis-
tinguishable from naturally arising virus
particles (Smotkin et al., 1975). We and
others soon applied this procedure to
studying the ability to introduce trans-
forming genes—oncogenes—via trans-
fection into previously untransformed
cells; the readout was the appearance of
foci of refractile cells in otherwise-flat
monolayer cultures.
The question was whether cells that
had been transformed through exposure
to a mutagenic carcinogen—methylcho-
lanthrene—contained oncogenic informa-
tion in their DNA, ostensibly the direct
product of mutagenesis; importantly,
these chemically transformed cells
gave no evidence of previous retrovirus
infections. By 1979, through use of trans-
fection, the DNA of the chemically trans-
formed cells was indeed shown to contain
transforming information (Shih et al.,
1979), which was followed up 3 years later
by the isolation through cloning of a trans-
fected human bladder carcinoma gene
(Shih and Weinberg, 1982; Pulciani et al.,
1982; Goldfarb et al., 1982). It seemed
that transfer of a single gene from cancer
cells to normal cells sufficed to transform
the latter.
Provocatively, this human oncogene
was a homolog of the Ras oncogene
discovered several years earlier by the
tumor virologists (DeFeo et al., 1981; Par-
ada et al., 1982; Der et al., 1982). This led
to yet another simplifying notion: that a
common repertoire of proto-oncogenes
residing in the mammalian genome could
be activated either by roving retroviruses
in animals or by chemical carcinogens in
human cells.
A further simplification followed close
on the heels of this realization. Thus,
DNA sequencing revealed that the
bladder carcinoma oncogene differed
from its normal proto-oncogene counter-
part by a single point mutation (Tabin
et al., 1982; Reddy et al., 1982; Tapa-
rowsky et al., 1982). For a brief moment
in 1982, there was the illusion that cancer
was as simple as it possibly could be—a
normal cell differed from its neoplastic
counterpart by one base out of three
billion!
From the point of view of the reduc-
tionist hoping that a small number of
molecular events might explain cancer,
things went downhill from there for the
next 30 years. Within weeks of the
announcement of the RAS point muta-
tion, there were those who said that
things could not be that simple. John
Cairns, who had studied the detailed
biology of human cancer development
(Cairns, 1978), pointed out, correctly,
that cancer development was a multistep
process, likely involving a succession of
rate-limiting steps, specifically stochasti-
cally occurring rare oncogenic muta-
tions. A single somatic mutation was un-
likely to explain this complexity.
Nonetheless, perhaps the number of
these essential mutation-driven steps
was relatively small. Indeed, by 1983,
two mutant genes, collaborating with
one another, were found to be capable
of transforming fully normal cells into
tumor cells (Land et al., 1983; Ruley,
1983). But even this was an illusion, as
only became apparent years later: While
experimental transformation of rodent
cells indicated two oncogenes sufficed
for transformation, the corresponding
human cells, which had long proven quite
refractory to experimental transformation,
required as many as five distinct intro-
duced mutant genes, perhaps even
more (Hahn et al., 1999). So two simple
notions—that small numbers of genes
would suffice to transform cancer cells,
and that all mammalian cells would follow
the same set of genetic rules during the
course of neoplastic transformation—
were undermined. Still, these were obser-
vations that could somehow be accom-modated in the thinking of reductionists
intent on puzzling out the genetic logic
of cancer pathogenesis.
Soon a new skirmish broke out. This
one focused on which classes of mutant
genes were really important for cell trans-
formation: oncogenes or the tumor
suppressor genes? A vocal advocate of
tumor suppressor genes—indeed a
founder of this field—dismissed the onco-
gene gold rush of the mid-1980s as an act
of lunacy, a band-wagon effect.likening
us to lemmings rushing en masse over
the edges of cliffs. This was another useful
lesson, at least for me. I came to appre-
ciate that the strongly held opinions of
widely respected senior professors
should be taken with large grains of salt.
As it turned out, the importance of both
classes of genes soon became apparent.
This notion acquired traction from the
Vogelstein work of 1989 demonstrating
a specific set of genetic changes asso-
ciated with distinct histopathological
stages of colorectal cancer pathogenesis
(Vogelstein et al., 1989; Fearon and
Vogelstein, 1990). The greater the degree
of progression a tumor exhibited, the
larger were the number of somatic muta-
tions affecting both oncogenes and
tumor suppressor genes. Hence, both
types of mutant genes seemed to be
important to tumor development and
both types coexisted within individual
cancer cells.
Most who were aware of this genetic
flow chart of tumor development read far
more into its conclusions than its authors
had intended. Some seized on the work
as evidence that a specific sequence of
mutations in a defined set of genes was
responsible for the appearance of most
human colorectal carcinomas. In truth,
the research revealed nothing more than
a probabilistic trend, with APC mutations
being, almost invariably, the first step,
followed by mutations of other genes,
such as K-RAS and p53, affecting some
colon tumors but not others. Moreover,
with the passage of time, the order of
acquisition of these secondary mutations
was found to vary from one colon tumor
to the next, and many were even found
to lack any sign of mutant RAS onco-
genes. Indeed, it became clear that colo-
rectal carcinomas follow highly variable
genetic paths en route from normalcy to
full-fledged neoplasia, so a simple linearCell 15narrative describing the development of
this class of tumors no longer seemed to
hold water.
All the while, the 1980s and 1990s wit-
nessed an explosive increase in the roster
of oncogene and tumor suppressor
genes, many of which were implicated in
human cancer development. These pro-
vided additional indication that cancer
development would not be simple. It
became clear that the identities of mutant
cancer-causing genes varied dramatically
from one type of tumor to the next. More-
over, even within a given type of cancer,
such as the much-studied colorectal
carcinomas cited above, there were no
uniform successions of genetic change.
Instead, each tumor seemed to represent
a unique experiment of nature, acquiring a
unique set of mutant genes and in an
unpredictable chronological order.
Keenly aware of these unsettling
trends, and holding out hope against
hope, Doug Hanahan and I reasoned in
1999 that there must nevertheless be
some underlying order beneath the
increasingly complex, if not chaotic,
genetic phenomenology of cancer.
Cancers seemed to present myriad
different faces to the world, but there
must be, we reasoned, certain underlying
commonalities. After all, cells only harbor
a finite array of phenotypes and intracel-
lular signaling circuits. In principle, one
way to depict these commonalities would
be to enumerate the specific intracellular
signaling channels that are deregulated
in most if not all types of human cancers.
However, at the time, as is still the case 15
years later, our understanding of how
most of these signal-processing circuits
actually operate was fragmentary.
For this reason, we side-stepped the is-
sues of signal transduction biochemistry
and focused instead on biology—on the
phenotypes of cancer cells and the
tumors that they formed (Hanahan and
Weinberg, 2000). There lay underlying
order, we reasoned, hiding beneath the
complex behaviors of cancer cells. We
ultimately converged on six biological
traits—‘‘hallmarks’’ as Doug called
them—that might well encompass almost
all of the biology of all types of human
tumors.
We fully expected the review article
that we cobbled together to disappear,
sinking quickly like a stone thrown into a7, March 27, 2014 ª2014 Elsevier Inc. 269
quiet pond. Like most of what we wrote
and write, we felt that, while this review
might serve to clarify our own thinking, it
was unlikely to resonate with the diverse
community of cancer researchers, many
of whom would dismiss it as simplistic.
As it turned out, we were wrong. Thou-
sands of articles referred to this review
in the decade after it appeared—a tribute
not to its writing, but instead to the pro-
found need of so many colleagues to
find some unifying themes among the
ever-growing mass of observations.
We renewed this attempt to find under-
lying order a decade later in 2011, when
we once again proposed the role of
hallmarks in helping conceptualize how
most human cancers arise (Hanahan and
Weinberg, 2011). By then, the six hall-
marks had grown to eight. Still, the overall
scheme seemed sound. Maybe human
cancers really did manifest a relatively
small set of features that governed their
behavior, even if each of those features
could be caused by still-unknown molec-
ular events.
There also seemed hope for order in
one of the more rapidly moving areas of
cancer research, which addresses the
biological processes of invasion and
metastasis. Carcinoma cells seemed to
employ a relatively small number of
shared mechanisms in order to escape
primary tumors and travel to distant sites.
Order seemed to be emerging out of this
lethal chaos (Thiery, 2002). Then reality
again reared its head: once disseminated
cancer cells enter into unfamiliar, often
inhospitable tissue microenvironments,
no simple rules seemed to describe their
mechanisms of adaptation—each type
of cancer cell and each distinct destina-
tion site appeared to require its own set
of adaptations, which are acquired only
with great difficulty, fortunately for the
cancer patient.
Starting in 2000, the few voices propos-
ing order and simplicity in cancer
research became increasingly drowned
out by a far more powerful chorus. The
generation of enormous data sets had
by then become routine and highly prized,
at least by some, as indicators of scientific
productivity. When I was a graduate
student, the evaluation of a single gel
electrophoresis channel required half a
day’s work; by 2000, thousands of such
channels could be run and analyzed in270 Cell 157, March 27, 2014 ª2014 Elsevierthis time. Expression array analyses could
now be performed to analyze the expres-
sion of thousands of genes in thousands
of tumors. Genome sequencing also
came of age and documented myriad
mutations afflicting individual cancer cell
genomes.
For many, generating large data sets
became an almost-addictive undertaking.
If two interacting entities—proteins for
example—were critical to a well-
established biological process, imagine
what studying two thousand proteins via
interactome analyses would yield! And
so, we entered, almost unconsciously,
into the epoch of ‘‘omics’’—studying
genomes, transcriptomes, proteomes,
epigenomes, kinomes, methylomes, gly-
comes, and matrisomes—each one of
which encompasses staggering amounts
of accumulated information. The relative
ease of generating vast amounts of data
became almost irresistible.
The currently embraced notion is that a
complex system can only be understood
if all of its moving parts are analyzed in
one sweeping overview. Such holistic
analyses should ideally describe the com-
plex reality of actual biological systems,
including that of cancer cells. More obser-
vational data should bring more insights,
as it did decades earlier. All one needs—
so the doctrine goes—are some compu-
tational algorithms to distill these data
sets into simple, accessible take-home
lessons that would provide mechanistic
insights into how complex systems actu-
ally operate, including how cancer cells
arise and how they respond to therapeutic
attack.
Amusingly, the same overconfident
presumption that my friends and I showed
toward the old-line cancer researchers in
the 1970s is palpable once again today,
now being exhibited by former phy-
sicists and mathematicians and bio-
informaticians: just tell us about the
working parts, they say, and we will
explain, indeed predict, how the complex
machine—a human cell—works!
In truth, the construction of truly useful
algorithms still seems to lie in the distant
future. While data mining, as it’s now
called, occasionally flags one or another
highly interesting gene or protein, the
use of entire data sets to rationalize how
and why a cancer cell behaves as it
does is still far beyond our reach. AtInc.most, one can develop correlations
between certain complex data sets (e.g.,
expression array analyses) and prog-
nosis, i.e., future behavior in the oncology
clinic. The gaping distance between these
data sets and a true understanding of
cancer biology is illustrated by the
amusing fact that two distinct expression
array analyses of cells in breast cancers
have been found to be equally useful in
predicting future clinical behavior of these
tumors but contain almost no genes and
thus proteins in common (Ein-Dor et al.,
2005; Fan et al., 2006).
Beyond these complex, currently
intractable large data sets, there are
problems that cancer researchers haven’t
even begun to confront. How do the tran-
scriptomes of cancer cells interact with
their mutant genomes to orchestrate can-
cer cell behavior? How do the differentia-
tion programs of the normal cells-of-origin
influence the behavior of their neo-
plastic descendants that have sustained
large numbers of genetic and epigenetic
changes? How do the multiple distinct
cell types that form the tumor microenvi-
ronment (composed of inflammatory and
immune cells and cells forming the micro-
vessels) intercommunicate with one
another and influence the behavior of
nearby neoplastic cells? Physicists have
wrestled unsuccessfully with the three-
body problem. What will become of us
who try to deal with eight or ten distinct
independent agents, each a distinct
stromal cell type that is recruited into a
tumor and interacts bidirectionally with
the other recent recruits?
Then there is the nettlesome problem of
multistep tumor progression: cancer is a
moving target, and whatever interactions
operate at one stage of tumor progression
are likely to change during the next one,
so that multiple solutions will need to be
worked out for individual tumors. Even
within an individual tumor at a single
stage of progression, there is an entirely
new dimension of complexity: deep-
sequencing analyses of tumor DNAs
now indicate multiple, genetically distinct
subpopulations whose representation
seems to vary dramatically from one
stage of tumor progression to another.
The data that we now generate over-
whelm our abilities of interpretation, and
the attempts of the new discipline of
‘‘systems biology’’ to address this
shortfall have to date produced few in-
sights into cancer biology beyond those
revealed by simple, home-grown intuition.
The coupling between observational data
and biological insight is frayed if not
broken.
We lack the conceptual paradigms and
computational strategies for dealing with
this complexity. And equally painful, we
don’t know how to integrate individual
data sets, such as those deriving from
cancer genome analyses, with other,
equally important data sets, such as pro-
teomics. This is most frustrating, since it
is becoming increasingly apparent that a
precise and truly useful understanding of
the behavior of individual cancer cells
and the tumors that they form will only
come once we are able to integrate and
then distill these data.
So, perhaps ironically, we have come
full circle, beginning in a period when
vast amounts of cancer research data
yielded little insight into underlying mech-
anisms to a period (1980–2000) when a
flurry of molecular and genetic research
gave hope that cancer really could be
understood through simple and logical
reductionist thinking, and finally to our
current dilemma. Once again, we can’t
really assimilate and interpret most of
the data that we accumulate.
How will all this play out? I wouldn’t
pretend to know. It’s a job, as one says
on these occasions, for the next genera-
tion. Passing the buck like this is an enor-
mously liberating experience, and so I’ll
keep on doing it!REFERENCES
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